Jan 01, 2013, 05.32 PM IST
Healthcare firm Aurobindo Pharma rose 2.11 percent to close at Rs 193.30 on the Bombay Stock Exchange on Tuesday as the company has received final approval from the US Food & Drug Administration to manufacture and market Rizatriptan Benzoate Tablets.
The company said the product was ready for launch. "Rizatriptan Benzoate Tablets 5mg (base) and 10mg (base) is the generic equivalent of Merck and company's Maxalt tablets and is indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 6 to 17 years old," Aurobindo said in a release.
The annual sale of product is approximately USD 300 million for 12 months ending March 2012, according to IMS. The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad.
Aurobindo has a total of 171 ANDA approvals from USFDA.
Aurobindo Pharm stock price
On December 10, 2013, at 12:01 hrs Aurobindo Pharma was quoting at Rs 307.30, up Rs 1.30, or 0.42 percent. The 52-week high of the share was Rs 312.00 and the 52-week low was Rs 127.15.
The company's trailing 12-month (TTM) EPS was at Rs 21.67 per share as per the quarter ended September 2013. The stock's price-to-earnings (P/E) ratio was 14.18. The latest book value of the company is Rs 100.93 per share. At current value, the price-to-book value of the company is 3.04.
Tags: Aurobindo Pharma
Action in Aurobindo Pharma
Video of the day
Dec 10 2013, 11:21
- in FII View
Dec 4 2013, 11:08
- in FII View
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.